Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill

Executive Summary

Makers of benzodiazepines could see wider use of their products by Medicare Part D enrollees, under a provision of the child health/Medicare legislative package that cleared the House Ways and Means Committee July 27

Related Content

More Research, Little Action On Comparative Effectiveness In Medicare Bill
ESRD Bundling Debate Shifts To Congress With Receipt Of CMS Report
New Comparative Effectiveness Center Should Ensure Evidence Quality – IOM
Part D Is “Stable” Feature Of Health Landscape; 2008 Enrollment Up 6%
Baucus Flags Comparative Effectiveness As Priority For Senate Medicare Bill
Drug Industry Boosts Lobbying Coffers; Amgen Doubles Its Expenditures
Comparative Effectiveness, Generic Biologics Draw Insurers’ Lobbying Efforts
Evidence-Based Medicine’s Success May Shift Definition Of Proprietary Data
Part B Competitive Purchasing Program Gains Flexibility In House-Passed Bill
Part D Enrollees Like Stability, Low Premiums, Analysis Of 2007 Plan Choices Finds



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts